Search

Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy

Publication: Bill

San Francisco, I. F., W. C. DeWolf, S. Rosen, M. Upton, and A. F. Olumi. 2003. Extended Prostate Needle Biopsy Improves Concordance of Gleason Grading Between Prostate Needle Biopsy and Radical Prostatectomy.

Pathologic quiz case. A symptomatic renal tumor. Juxtaglomerular cell tumor

Publication: Bill

Kuten, A., A. Olumi, J. Goldsmith, R. A. Monahan-Earley, A. M. Dvorak, and E. M. Genega. 2004. Pathologic Quiz Case. A Symptomatic Renal Tumor. Juxtaglomerular Cell Tumor.

Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen

Publication: Bill

San Francisco, I. F., M. M. Regan, A. F. Olumi, and W. C. DeWolf. 2004. Percent of Cores Positive for Cancer Is a Better Preoperative Predictor of Cancer Recurrence After Radical Prostatectomy Than Prostate Specific Antigen.

Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer

Publication: Bill

Zhang, X., T. G. Jin, H. Yang, W. C. DeWolf, R. Khosravi-Far, and A. F. Olumi. 2004. Persistent C-FLIP(L) Expression Is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer.

Surgical management of scrotal lymphedema using local flaps

Publication: Bill

Halperin, T. J., S. A. Slavin, A. F. Olumi, and L. J. Borud. 2007. Surgical Management of Scrotal Lymphedema Using Local Flaps.

MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L)

Publication: Bill

Li, W., X. Zhang, and A. F. Olumi. 2007. MG-132 Sensitizes TRAIL-Resistant Prostate Cancer Cells by Activating C-Fos/C-Jun Heterodimers and Repressing C-FLIP(L).

Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model

Publication: Bill

Zhang, L., X. Zhang, G. W. Barrisford, and A. F. Olumi. 2007. Lexatumumab (TRAIL-Receptor 2 MAb) Induces Expression of DR5 and Promotes Apoptosis in Primary and Metastatic Renal Cell Carcinoma in a Mouse Orthotopic Model.

Search

Search results

Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy

Pathologic quiz case. A symptomatic renal tumor. Juxtaglomerular cell tumor

Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen

Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer

Surgical management of scrotal lymphedema using local flaps

MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L)

Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model

Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia

Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer

Models of care and NCCN guideline adherence in very-low-risk prostate cancer